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chronic obstructive pulmonary disease (COPD, 27%), renal dysfunction (27%), 
stroke (21%), other cardiovascular disease (CVD, 78%). NNT to prevent  
one hospitalization annually (budget impact per HF patient in sample): 12 (-$89) 
ACE-inhibitor/ARB, 15 (-$60) beta-blockers, or 11 (-$123) other cardiovascular 
drugs; -27 ($92) hypertension, 11 (-$179) psychological disorder, -12 ($133) CIHD, -
12 ($118) diabetes, 13 (-$98) hyperlipidemia, -10 ($97) COPD, -8 ($116)  
renal dysfunction, -12 ($60) stroke, -8 ($322) CVD. CONCLUSIONS: Increasing 
enrollment in state Medicaid plans and other entitlement programs call for  
more deliberate, proactive and cost-effective disease and risk management  
of plan enrollees. Substantive savings to Medicaid can be achieved with  
small changes in the prevalence of common comorbid conditions or prescribing 
rates.  
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HOSPITAL BUDGET IMPACT OF READMISSION PENALTIES AND BUNDLED 
PAYMENTS: POTENTIAL IMPACT OF CORONARY STENT PLATFORMS  
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OBJECTIVES: The Affordable Care Act established the Hospital Readmission 
Reduction Program (HRRP) and the Bundled Payments for Care Initiative (BPCI), 
which may reduce Medicare payments to hospitals. We assessed these 
programs’ impact on hospital budget, focusing on the potential to reduce 
penalties via improved short-term percutaneous coronary intervention (PCI) 
outcomes. METHODS: A budget impact model was developed to quantify the 
financial penalties associated with HRRP and the difference between fee-for-
service and bundled payments under BPCI for a hospital. HRRP penalties were 
associated with excess readmissions for patients admitted with acute 
myocardial infarction (AMI), pneumonia, and heart failure. The model also 
computed payment reductions under BPCI for all PCI patients regardless of 
diagnosis. An example hospital with high volume catheterization lab (1000 
PCIs/year; 50% Medicare) and total Medicare DRG-based payments of $110 
million/year was considered. The hospital was assumed to have excess 
readmission ratios at the seventy-fifth percentile for each condition. Based on 
recent clinical trials of stent platforms, we assumed an absolute 1% reduction in 
PCI-related readmission due to AMI and revascularization over 30 days following 
PCI. RESULTS: Total HRRP penalties for the example hospital were calculated to 
be $669,025, with $199,130 additional reduction in payments under BPCI.  
Our model projected that reducing readmission post-PCIs by 1% would  
reduce excess readmission ratio for patients with AMI from 1.052 to 1.037  
and thus HRRP penalties by $80,975. Total cost of care for the 500 Medicare 
patients receiving PCI was reduced by $43,791 due to reduction of subsequent 
clinical events, a savings accrued by hospitals under BPCI, resulting in net 
hospital savings of $124,766. Achieving these savings with newer stent platforms 
would result in effective hospital savings of $156/stent. CONCLUSIONS: A 1% 
reduction in PCI-related readmissions may substantially reduce penalties  
under HRRP and BPCI. Such reductions may be achievable using new stent 
platforms.  
 
PCV43  
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OBJECTIVES: Despite national and international guideline recommendations, 
only a small proportion (estimated in 39%) of ST elevation myocardial infarctions 
(STEMI) that arrive in the 8-hour "therapeutic window" in Colombia receive 
thrombolytic treatment; our objective was to estimate the budget impact of a 
gradual implementation of this therapeutic approach. METHODS: In our excel 
based model we applied ISPOR's principles of good practice for budget impact 
analysis. The perspective was from the Colombian health system; we used a 5-
year time horizon (2012-2016). The model compared two different scenarios: 
continuing the current practice, with no increase in the proportion of 
thrombolized patients, while the other (Scenario 2) assumed a gradual increase 
(5 percentage points) of thrombolized patients, and an increase in tenecteplase 
use from (3 to 25% of all patients) along the five year period. RESULTS: Our 
estimated total cost of STEMI in Colombia for 2012, with 984 patients 
thrombolyzed nationwide, was US$728,291. With an increase in the use of 
thrombolysis (Scenario 2) the cost would increase by US$ 42,270 during the 
second year, US$87,596 during the third year, US$136,051 in the fourth year and 
US$187,716 in the fifth year (with a 15% overall increase in the number of 
thrombolyzed patients). This cost increase is due to an increase in the target 
population (estimated by official demographic projections), an increase in the 
proportion of patients with myocardial infarction receiving thrombolyisis and an 
increase in those receiving tenecteplase instead of streptokynase. 
CONCLUSIONS: Our country needs to allocate resources to prevent and treat 
cardiovascular diseases; applying current standards established in evidence-
based guidelines of myocardial infarction treatment should be an affordable 
investment.  
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COST OF PHARMACOTHERAPEUTIC MANAGEMENT OF HYPERTENSION IN A 
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OBJECTIVES: The study assessed economic burden of pharmacotherapy in 
hypertension management on the National Health insurance Scheme (NHIS) of 
Nigeria, Health Maintenance Organizations (HMOs), the individual patients, and 
the companies as well as the economies of antihypertensives selection. 
METHODS: Two hundred and fifty case notes of hypertensive patients attending 
out-patient-department of the hospital (between August 1st – November 30th, 
2011) were randomly selected. Selection criteria required that patients must  
be on at least an antihypertensive and first diagnosed after 2003. These  
were assessed for costs of pharmacotherapeutic management of hypertension  
as well as drug funding status.Requisite patients’ information extracted  
from case notes included: hospital number, age, gender, occupations, drugs, 
dosages and patients’ drug funding status. Drugs’ prices were obtained from  
the hospital billing guide. Data analysis was carried out using Microsoft  
excel and SPSS v16.0 for windows. RESULTS: Two hundred and eight of the 
selected case notes met the study criteria out of which 125 (60.1%) were males, 
while 83 (39.9%) were females. Most of the patients work for the government 98 
(47.1%). Others either work for private companies 51 (24.5%) or are self-employed 
25 (12%). Retirees constituted 11.5% of the lot while 4.8% were unemployed. 
Diuretics were the most economical at an average monthly cost per prescription 
of  858.6 ($5.51) and was closely followed by the beta-blockers at  1,101.1 ($7.07). 
The total estimated monthly cost of the antihypertensives prescribed in the 
study was  892,650 ($5730.93). HMOs having 104 (50.0%) of the cohort as enrollees 
incurred most of the cost at  446,325.0 ($2865.47). NHIS and Companies with 75 
(36.0%) and 17 (8.2%) of the enrollees respectively incurred  321,354.0 ($2,063.14) 
and  73,197.3 ($469.94). Private patients 12 (5.8%) incurred the least at  51,773.7 
($332.39). CONCLUSIONS: HMOs and NHIS incurred most of the cost of 
antihypertensives prescribed and diuretics were the most economical of all.  
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OBJECTIVES: Pharmacoeconomic analysis of two schemes antihypertensive 
therapy: diroton (lisinopril) (tab. 10 mg 128, Gedeon Richter) compared with lipryl 
(tab. 10 mg 130, BHFZ) and two regimens with fixed combinations of ACE 
(captopril) + diuretic (hypothiazide): kapozyd (tab. 50mh/25mh 130, BMS) 
compared with captopres-D (tab. 50mh/25mh 120, Darnitsa) for one year in 
Ukraine. METHODS: Cost minimization analysis, budget impact analysis and 
analysis of missed opportunities were used. RESULTS: In condition of equal 
efficacy lipryl is less expensive (costs of treatment per patient for year - 292 UAH) 
compared with diroton (costs of treatment per patient for year - 620.50 UAH). 
Indicator of missed opportunities in the transition to less expensive drug is 
1.125. According to official statistics of Ministry of Health in Ukraine there are 
12.1 millions patients with hypertension, or 32.2% of the adult population. The 
costs of lipryl treating this population are 3540 millions UAH, for diroton - 7522 
millions UAH. The transition to lipryl economy of budgetary funds will be 3982 
millions UAH. The analysis of two schemes of antihypertensive therapy with 
fixed combinations of ACE inhibitors (captopril) + diuretic (hypothiazide) shows 
that in condition of equal efficacy captopres-D is less expensive (costs of 
treatment per patient for year - 295.65 UAH) compared with kapozyd (costs of 
treatment per patient for year – 511 UAH). Indicator of missed opportunities is 
0.728. Given the number of patients with hypertension, the costs of captopres- 
D treating this population will be 3584 millions UAH, for kapozyd - 6194.6 
millions UAH. In condition of budget financing in the transition to captopres-D 
economy of budgetary funds will be 2610.6 millions UAH. CONCLUSIONS: The 
results of the analysis prove the economic feasibility of domestic 
antihypertensive drugs.  
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ECONOMIC IMPACT OF SWITCHING TO FIXED-DOSE COMBINATION THERAPY 
FOR JAPANESE HYPERTENSIVE PATIENTS: A RETROSPECTIVE COST ANALYSIS  
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OBJECTIVES: The prescription of fixed-dose combinations (FDC) of 
antihypertensive drugs has increased rapidly since the relaxation of the 
prescription-term restriction. In this study, we used the opportunity of this 
policy change in Japan to examine the economic benefits of switching to FDC. 
METHODS: Claims data from 64 community pharmacies located in Tokyo were 
used to identify hypertensive patients under continuous treatment with 
angiotensin-receptor blockers (ARBs). Patients switching to FDC between 
December 2010 and April 2011 were compared to patients who did not receive 
FDC (control group). Changes in annual total and antihypertensive drug costs 
were compared for both groups, using a difference-in-differences approach to 
adjust for patient characteristics and use of concomitant medication. RESULTS: 
There were 542 patients who switched to FDC and 9664 patients in the control 
group. No significant differences were observed between the 2 groups, except for 
antihypertensive drug use patterns before the policy change. The switch to FDC 
was associated with annual savings of 6151 yen (US$87.70) in total drug costs 
and 10,420 yen (US$124.20) in antihypertensive drug costs. Approximately 20% of 
the FDC patients, however, switched from ARB alone and their treatment costs 
increased by 3795 yen (US$37.10). CONCLUSIONS: For hypertensive patients who 
required ARB-based combination therapy, switching to FDC drugs had a 
significant cost-saving effect. However, the policy change of relaxing the 
prescription-term restriction could encourage aggressive treatment, i.e., 
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switching to a combination therapy from monotherapy, regardless of medical 
conditions. Further research is required to evaluate the possible negative aspects 
of FDC drugs.  
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COMPARATIVE ANALYSIS BETWEEN PROSTHESIS TYPES  
Culler S1, Levitsky S2 
1Rollins School of Public Health at Emory University, Atlanta, GA, USA, 2Harvard Medical School, 
Boston, MA, USA  
OBJECTIVES: This study reports the results of an economic model predicting 
differences in lifetime cost of health care services consumed following heart 
valve surgery by prosthesis type. This model examines: Mechanical Valve (MV), 
Stented Tissue (ST) and the emerging Transcatheter Valve (replacement surgery 
only) METHODS: The economic model assumes a 55-year-old valve disease 
patient requiring surgery with a 25 year post-surgery life expectancy. Peer 
reviewed journals provided estimates of complication event rates by prosthesis 
type. The model estimated costs for two possible types of valve replacement 
procedure at year 15 for patients receiving initial ST prosthesis: 1) a second ST 
surgery (ST), or 2) a transcatheter valve in valve (ViV) approach. Average annual 
inflation rate of 3% was used. Clinical events included: initial valve surgery; 
thrombotic events; bleeding events; warfarin and monitoring; echo monitoring; 
paravalular leak; endocarditis; pacemaker insertion following valve surgery; re-
operation due to structural valve deterioration; and clinical complications 
following transcatheter procedures. RESULTS: Cumulative costs were estimated 
to be $124,200 using MV during initial surgery; $183,600 using STs; and $478,048 
using ViV. The MV resulted in lower expected health care costs in every year 
versus either ST approaches. The MV choice at the initial surgery results in a 
lifetime cost saving of $59,400 and $353,882 compared to using STs and ViV, 
respectively. The MV approach obtains the majority of its savings after year 15. 
CONCLUSIONS: Our model estimates changing initial prosthesis choice to the 
MV in the estimated 20,000 ST valve surgeries performed annually in the U.S. 
among patients below age 65 would result in approximately $1.2 billion lifetime 
reduction in direct health care expenditures over the next 25 years, The majority 
of savings occur when these patients would be Medicare Beneficiaries.  
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A MODEL UTILIZING PREOPERATIVE MARKERS TO PREDICT PATIENTS 
ASSOCIATED WITH HIGH COST IN OPEN VERSUS ENDOVASCULAR REPAIR OF 
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OBJECTIVES: We examined predictors of high cost for abdominal aortic 
aneurysm (AAA) repair in order to identify patients who are likely to require 
more intensive treatments. In general, younger, healthier patients with 
unfavorable anatomy are good candidates for Open AAA repair while older 
patients with significant comorbidities and favorable anatomy have better 
results when treated with the less invasive endovascular aneurysm repair (EVAR) 
procedure. Indeed, a sizable number of patients present with AAA who could be 
treated safely following either modality. METHODS: A dataset of elective AAA 
repairs totaling 389 Fletcher Allen Health Care patients (230 EVAR, 159 OPEN) was 
analyzed retrospectively over the time period January 1, 2003 through December 
31, 2011. Direct and indirect costs were obtained along with length of stay (LOS) 
and other clinical and behavioral parameters. Models to predict being in the 
upper quartile of cost were developed using logistic regression. RESULTS: 
Significant predictors of being in the upper quartile of costs for Open patients 
were history of treated COPD, previous bypass surgery, transfer from hospital, 
and age >70, with area under ROC=0.726. Predictors for EVAR patients were 
presence of iliac aneurysm(s), CABG/PTCA within the past 5 years, ejection 
fraction ≤30%, on beta blocker, creatinine ≥1.5mg/dl, and current smoker, with 
area under ROC=0.784. For EVAR patients, who had an average LOS of only 1-2 
days, total costs ranged from $21,904 to $47,511. For Open patients, who had an 
average LOS of 5-7 days, these figures ranged from $13,549 to $35,685 in constant 
dollars. CONCLUSIONS: This wide range of total cost invites the introduction of 
resource utilization tools based on cost predictors that can optimize clinical 
outcomes and reduce costs at the individual patient level.  
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OBJECTIVES: Platinum chromium everolimus-eluting stents (PtCr-EES) were 
compared to cobalt chromium everolimus-eluting stents (CoCr-EES) in the 
randomized controlled PLATINUM trial. Clinical outcomes including rates of 
target vessel revascularization (TVR), myocardial infarction (MI), and cardiac 
death have been reported through 2 years (n=1507), with 3 year data to come. An 
economic analysis was performed to assess the cost-effectiveness of PtCr-EES 
versus CoCr-EES accounting for stent reimbursement practice, in which payers 
reimburse by procedure but hospitals bear the direct cost of stents. METHODS: A 
Markov model was used to compare costs from payer (Medicare) and hospital 
perspectives of PtCr-EES versus CoCr-EES over two years, based. The model 
explicitly accounted for costs (2013) of differences in index procedure and long-
term cardiac events. Payer costs for the index procedure were increased only for 
those bailout (unplanned) stents associated with major complicating conditions 
(MCC; aortic dissections or extended length of stay), while hospital costs 
reflected all stents used (bailout or planned). Similarly, those MIs concurrent 
with TVR and all stent thromboses were modeled as MCCs of the TVRs, not 
separate events. RESULTS: PtCr-EES was cost saving versus CoCr-EES by 
$277/patient from a payer perspective, due to reduced costs for bailout stenting 
during the index procedure (3.1% vs. 4.2%) and TVR over 2 years (4.3% versus 
5.4%). Probabilistic sensitivity analysis found PtCr-EES was economically 
dominant (more effective and less costly) in 81% of replications. From a hospital 
perspective, PtCr-EES saved an additional $151/patient in reduced stent 
acquisition costs. A detailed costing analysis would be required to determine 
how much of the $277/patient reduction in reimbursement reflects reduced 
hospital costs, and thus total societal savings. CONCLUSIONS: PtCr-EES was 
found to be cost saving versus CoCr-EES from both payer and hospital 
perspectives, primarily due to reduced TVR over 2 years. Total societal savings 
may be up to $428/patient.  
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OBJECTIVES: We examined the average number of reinterventions, average 
reintervention costs (ARC), and the average total costs (ATC) for the latest 
iteration of a heparin-bonded ePTFE Stent-Graft versus a bare metal stent (BMS) 
in patients treated for atherosclerotic disease of the superficial femoral artery 
(SFA). ATC includes costs for the initial implant, reinterventions, and follow-up 
care. METHODS: As previously reported by Saxon (2011) and Ansel (2011), two 
independent clinical studies of the Stent-Graft were recently completed. One-
year results from the multicenter, single-arm, VIPER trial were compared to the 
one-year results of the BMS arm from the three-year, multicenter, randomized 
VIBRANT trial. The Stent-Graft used in the VIPER trial is the latest iteration of the 
device in use today. Patient characteristics were similar in both trials. Cost data 
from the Centers for Medicare and Medicaid Services was used to estimate ARC 
and ATC for all patients, and secondarily, for patients oversized ≤20% at the 
proximal edge of the Stent-Graft (instructions for use recommend 5-20% 
oversizing). RESULTS: The Stent-Graft group trended toward fewer 
reinterventions per patient than the BMS group (0.36 vs. 0.63, P=0.15), lower ARC 
($3,143 vs. $4,346, P=0.38), and higher ATC ($16,482 vs. $14,987, P=0.36) through 
one year follow-up. Patients oversized ≤20% trended toward fewer 
reinterventions per patient (0.21 vs. 0.63, P=0.08), lower ARC ($1,588 vs. $4,346, 
P=0.05), which was statistically significant, and lower ATC ($14,524 vs. $14,987, 
P=0.78) versus the BMS. CONCLUSIONS: Based on the comparison of one-year 
follow up data, the Stent-Graft trended toward reducing reinterventions and ARC 
for all patients being treated for atherosclerotic SFA disease compared to BMS. 
When oversized ≤20% at the proximal edge, the Stent-Graft reduced ARC 
(statistically significant finding) and trended toward reducing reinterventions 
and ATC. Long-term follow up will be needed to measure the benefits beyond 
one year for all patients.  
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OBJECTIVES: Estimate the real-world economic impact of switching from 
metoprolol, the most commonly prescribed β-blocker for hypertension in the US, 
to nebivolol, a novel well-tolerated β-blocker with high β1 selectivity and 
vasodilatory properties, for hypertension treatment. METHODS: Retrospective 
database analysis with a pre and post study design was conducted using 
MarketScan database (2007-2011). Hypertensive patients continuously treated 
with metoprolol for at least six months (pre-period) and then switched to 
nebivolol for at least six months (post-period) were identified. The first nebivolol 
dispensing date was defined as the index date for switching. Data were collected 
for the two six-month periods pre- and post- switching. Monthly health care 
resource utilization and health care costs pre and post switching were calculated 
and compared using Wilcoxon and paired t-tests. Medical costs at different years 
were inflated to the 2011 dollar using medical component consumer price index. 
RESULTS: A total of 2259 patients, with a mean age of 60, met the selection 
criteria. Among them, 52% were male, 37% had cardiovascular (CV) disease. After 
patients switched to nebivolol, there were statistically significant reductions in 
the number of all-cause hospitalization (p<0.01), CV related hospitalization 
(p<0.01), outpatient visits (p<0.01), and CV related emergency room (ER) visits 
(p=0.01). Monthly inpatient costs reduced $106 (p<0.01), while monthly drug cost 
increased $49 (p<0.01). There were reductions on costs of outpatient and ER 
visits, but the differences were not statistically significant. Overall health care 
cost reduced $63 per patient per month. Sensitivity analysis on length of 
medication exposure found similar results. CONCLUSIONS: This real-world 
study finds that patients who switched from metoprolol to nebivolol had a lower 
overall health care cost after switching.  
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